recurrent multiple myeloma (DBCOND0025643)

Identifiers

Synonyms

Recurrent Multiple Myeloma

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Bendamustine	An antineoplastic nitrogen mustard agent used in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy.	Cytochrome P450 1A2enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03618602	Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients	No drug interventions	treatment	1	unknown_status
NCT03798678	CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma	Carfilzomib Dexamethasone Telaglenastat	treatment	1	active_not_recruiting
NCT04883242	Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma	Carfilzomib Dexamethasone Isatuximab Pomalidomide	treatment	2	recruiting
NCT05950113	CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma	Cyclophosphamide Fludarabine	treatment	1	withdrawn
NCT03770260	Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment	Ixazomib Pevonedistat	treatment	1	completed
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	ABSK-091 Adavosertib Afatinib Binimetinib Capivasertib Copanlisib Crizotinib Dabrafenib Dasatinib Defactinib Erdafitinib GSK-2636771 Ipatasertib Larotrectinib Methane Nivolumab Osimertinib Palbociclib Pertuzumab Relatlimab Sapanisertib Sulfate ion Sunitinib Taselisib Trametinib Trastuzumab Trastuzumab emtansine Tyrosine Ulixertinib Vismodegib	screening	2	active_not_recruiting
NCT06203912	Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma	No drug interventions	treatment	1	recruiting
NCT03389347	High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia	No drug interventions	other	Not Available	recruiting
NCT05981209	Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies	No drug interventions	treatment	1	recruiting
NCT04764942	Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial	No drug interventions	treatment	1 / 2	recruiting
NCT03031730	Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma	No drug interventions	treatment	1	terminated
NCT06232044	Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma	No drug interventions	treatment	1 / 2	not_yet_recruiting
NCT02101944	Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	No drug interventions	treatment	1	completed
NCT05847569	Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma	No drug interventions	treatment	2	recruiting